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Executive summary
Soluble ST2 is a novel cardiac biomarker that reﬂects cardiac injury and the response to
treatment. Previous studies showed that ST2 has less confounding and more speciﬁc than
NT-proBNP.  ACCF/AHA  has  proposed  2013  Guidelines  for  the Management  of  Heart
Failure that includes ST2 in the recommendations. In the research proposal, we will assess
the clinical role of serum ST2 level in cardiac non-coronary valve surgical patients.
We will  recruit  70 patients who undergo cardiac non-coronary valve operations.  Serum
levels of ST2 and NT-proBNP and troponin-T will be measured at preoperative baseline,
postoperative 24 hours, and postoperative 5 to 10 days in the routine blood sampling. The
endpoints  include hospital  mortality,  all-cause mortality,  unexpected ICU return,  MACE,
time  to  extubation,  and  total  length  of  stay.  We  will  also  collect  various  preoperative,
operative, and postoperative variables, such as EuroScore-II. Their relationships will  be
analyzed.
We expect to demonstrate the superior role of ST2 to NT-proBNP and other variables in
risk stratiﬁcation and outcome prediction and assessment in our cohort.
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Backgrounds
Soluble ST2 (sST2) is a novel biomarker (Dieplinger et al. 2009) of ﬁbrosis (Moore and
Januzzi 2010) that reﬂects cardiac dysfunction such as remodeling or post-injury scaring
(Sanada et  al.  2007,  Weir  et  al.  2010,  Willems et  al.  2013,  Díez  2008).  According  to
previous  research,  its  trending  has  superior  signal-to-noise  and  clinical  relevance  for
cardiac  prognosis  to  conventional  biomarkers  for  heart  failure  such  as  NT-proBNP
(Weinberg  et  al.  2002,  Pascual-Figal  et  al.  2011a,  Santhanakrishnan et  al.  2012).  For
valvular  heart  disease  patients  and  their  outcomes,  we  would  like  to  investigate  the
association and predictive value of ST2 in cardiac surgical non-coronary valve patients.
Conventional biomarkers for assessing heart failure are BNP / NT-proBNP. But they have
various confounders like age, BMI, and renal disease (Mueller and Dieplinger 2013). When
heart perceives stress, their serum levels begin to rise and their random variations are
high.  Thus  their  role  of  monitoring  heart  failure  prognosis  may  be  unsatisfactory  for
physicians  who need timely  responses (Willems et  al.  2013,  Bayes-Genis  et  al.  2011,
Rehman et al. 2008).
Soluble  ST2  can  reﬂect  the  process  of  cardiac  remodeling  and  myocardial  post-injury
ﬁbrosis in heart failure (Rehman et al. 2008, Schmitz et al. 2005, Moore and Januzzi 2010),
and so it  has much less  confounding than conventional  BNP/NT-proBNP (Mueller  and
Dieplinger 2013). When ST2 serum levels climb, it means there is considerable myocardial
damage (Broch et al. 2012, Lupón et al. 2013). After treatment we can check if ST2 begins
to drop to assess whether the treatment works (Pascual-Figal et al. 2011a, Chen et al.
2013). Even in the asymptomatic patients (Wang et al. 2013), if the ST2 serum levels are
higher than the cutoﬀ 35 ng/ml, it means there is signiﬁcant cardiac damage (Mueller and
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Dieplinger  2013,  Januzzi  2013).  We  can  monitor  ST2  serum  level  to  predict  disease
occurrence (Chen et al. 2013) and make treatment plans as early as possible (Boisot et al.
2008, Manzano-Fernández et al.  2012). In addition ACCF/AHA has proposed the 2013
Guideline for the Management of Heart Failure that includes ST2 in the recommendations
(Yancy  et  al.  2013).  ST2  and  NT-proBNP can  work  together  for  better  sensitivity  and
speciﬁcity (Pascual-Figal et al. 2011a, Bayes-Genis et al. 2011, Sabatine et al. 2008).
As above, there are also various prior research studies that demonstrated the association
of  sST2  with  acute  and  chronic  heart  failure  (Mueller  et  al.  2008,  Shah  et  al.  2009,
Wojtczak-Soska et al. 2013, Daniels et al. 2010, Bhardwaj and Januzzi 2010, Henry-Okafor
et al. 2012, Manzano-Fernández et al. 2011, Shah and Januzzi 2010, Weinberg 2003).
Aims
1. To stratify the operation risk of valvular heart patients by preop sST2 and other
known preop variables;
2. To correlate the operation outcomes of valvular heart patients by postop sST and
other known postop variables;
3. To compare sST2 and other known predictive variables.
Impact
Currently we can implement ST2 in the following scenarios:
1. Health checkup and outpatient screening (Wang et al. 2013);
2. Acute inpatients and routine assessments (Díez 2008, Aldous et al. 2012, Pascual-
Figal et al. 2009);
3. Post-treatment and prognosis for the recovery evaluation, maybe as long as three
to six months (Bayes-Genis et  al.  2011, Lupón et  al.  2013, Pascual-Figal  et  al.
2011b, Ky et al. 2011).
Methods
We will collect ST2, and other cardiac biomarkers at diﬀerent time points of cardiac valve
surgical patients and investigate their relationships with diﬀerent outcome measures and
also may compare the performance of these biomarkers on predicting various outcomes
(Gaggin et al. 2014).
Design
Prospective observational longitudinal clinical study
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Data collection overview
(1) Serum biomarker levels of ST2, NTproBNP, and troponin-T from blood sample drawing
at the same time of  clinical  routine blood drawing: preop, postop 24-hour,  postop 5-10
days; three time points.
(2) ST2 will be done by special kits sponsored by the vendor. NTproBNP and troponin-T will
be measure in hospital central lab.
(3) Preop, op, postop, and outcome variables will be collected as the following details.
Expected Difficulties and Troubleshooting
Since the study does not alter routine clinical practice, little resistance from patients and
family  is  anticipated.  Thorough  explanation  of  the  informed consent  will  be  helpful  for
recruiting participating patients.
Inadequate sample size or  insuﬃcient  power to detect  diﬀerence may be encountered.
Since we have many dependent variables or outcome variables, we may select the some to
present.
Procedures
Ethical Considerations
The research protocol will be evaluated by the institutional review board.
All participating patients will have thorough understanding of the study regarding the aims
and  potential  risks  as  explained  by  the  research  staﬀ  members.  They  also  sign  the
informed consensus personally or by a qualiﬁed proxy.
We have a conﬂict of interest to declare: the laboratory kits are partially sponsored by the
local  distributor,  Health  One  Network  Co.,  Ltd.  New  Taipei  City  Taiwan,  (telephone:
886-2-22993688--x13; cellphone: 886-930142606).
Cohort definition
We will prospectively recruiting the valvular heart patients who are admitted for elective
corrective operations in Far Eastern Memorial Hospital.
The recruited patients must meet all of the inclusion criteria: adult with age over 20 years,
pure  valvular  operations,  elective  setting,  single  or  multiple  valves,  conventional  or
minimally-invasive  approach,  either  without  or  with  previous  cardiac  or  major  aorta
operations.
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The exclusion criteria are: pregnant, combined concurrent major cardiac procedures such
as coronary or aorta operations, non-elective settings such as urgent or emergency, refusal
of participation by the patient or family due to any reason.
If the inclusion or exclusion of a case is in doubt, the decision is made by the consensus or
majority of principal investigators (PI and co-PI).
Data collection
Each patient  will  have three serum samples collected before operation,  24 hours after
operation, and around one week (from ﬁve to ten days) after operation. The blood drawing
will be made concurrently with other laboratory tests as needed clinically. There is no extra
blood drawing purely just for the study. For cardiac biomarkers, we will measure sST2, NT-
proBNP, and troponin-T.
Our routine cardiac surgery database will also collect preop, op, and postop variables for
all the patients, such as EuroScore-II. The outcome-related variables will include: time to
extubation (TOE), intensive care unit (ICU) time, total length of stay (LOS), and hospital
mortality.
The variables for each patients are listed but not limited as below:
Biomarkers (preop, postop 24 hour, postop 5-10 days): sST2, NT-proBNP, troponin-T (
Table 1).
Biomarkers Preop Postop 24 hour Postop 5~10 days
sST2
NT-proBNP
Troponin-T
Preop: Birthday,  date  of  operation,  op  diagnosis,  last  preop  LVEF,  last  preop  RVSP
(SPAP), creatinine, dialysis or not, diabetes, hypertension, COPD;
Op: operation procedure, op time, ischemia time, pump time
Postop: time to extubation, ICU time, total LOS, unexpected ICU return, hospital mortality
(also date), major adverse cardiac event (MACE) (also date), ﬁrst postop LVEF, and ﬁrst
postop RVSP (SPAP).
Table 1. 
Biomarker sampling schedule
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Laboratory bench work
To measure sST2 serum levels, we will use the kits and protocols as advised by the vendor
(Mueller and Dieplinger 2013). To measure NT-proBNP and troponin-T serum levels, we
will send the samples to hospital central lab for result reporting since they have been our
clinical routines.
Data Analysis
We plan to recruit 70 patients and measure three serum samples per case. There will be
210 laboratory tests. Due to budget limitation, we set the sample size to be 7, since we can
only aﬀord 210 laboratory tests. We set the alpha-level to be 0.05.
The outcome variables (dependent variables) will be the following and we will select more
appropriate  variables  to  present  according  to  the  interim analysis  results.  The primary
endpoints  include:  hospital  mortality,  all-cause  mortality,  unexpected  ICU  return,  and
MACE. The secondary endpoints include: time to extubation, ICU time, and total LOS.
We will transform several variables to facilitate analysis. Renal function will be graded by
GFR (glomerular  ﬁltration  rate)  as  estimated  by  creatine-related  formulae.  Comorbidity
such as diabetes or hypertension will be determined by clinical judgment. For biomarker
analysis (sST2, NT-proBNP, troponin-T), in addition to absolute values, we will use relate
values for better demonstrate the change from baseline and the trends. Relative serum
level (RSL) is a dimensionless value deﬁned as the ratio of serum level to the baseline
(level divided by baseline).
For comparing scale or ordinal (quasi-scale) variables, we will use Mann-Whitney U test for
two  groups  and  Kruskall-Wallis  test  for  three  or  more  groups.  For  comparing  nominal
variables, we will use Fisher’s exact test. For comparing time-event variables, we will use
log-rank test. For modeling predictions, we will  choose appropriate statistical regression
methods based upon dependent variables. For scale dependent variable, we will use linear
or log-linear regression models depending the likelihood of normality violation. For binary
dependent variables, we will use logistic regression model. For time-event variables, we will
use  Cox  regression  model.  For  evaluating  biomarker  performance  on  accuracy  of
classiﬁcation, we will receiver operating characteristic (ROC) analysis. The truth variables
will  be one of  the outcome variables and the classiﬁer variables will  be ordinal-ranged
biomarker absolute level or RSL. The tentative optimal cutoﬀ values for each biomarker
may be proposed depending on the outcome variables or clinical scenarios.
The backbone for the results presentation will be: cohort background statistics, time trends
of biomarkers, biomarker and predictors for the outcomes, and comparisons of biomarkers.
The statistical software we used will be Stata/MP 13.1 for Mac (64-bit Intel).
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Timetable
(1) ST2 and other cardiac biomarker lab assay;
(2) Statistical analysis of the study;
(3) Interpretation and implement of the study results.
(Table 2)
Time (month) 1-2 3-4 5-6 7-8 9-10 11-12
Data collection @ @ @ @
Statistical analysis @ @ @ @
Result interpretation @ @ @
Report writing @ @ @
Acknowledgements
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Table 2. 
Research working timetable
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